Kathleen M. Metters

Dr. Metters was previously president and CEO of Lycera Corp. and held a number of leadership positions over more than two decades at Merck & Co. Under her leadership Lycera developed a pipeline of immune modulator programs which led to an exclusive global collaboration with Celgene in 2015. Dr. Metters began her tenure at Merck & Co as a research scientist and progressed to become head of Worldwide Basic Research. During this time Dr Metters was integral to the discovery of the asthma drug Singulair® and subsequently chaired the Worldwide Business Strategy team for the respiratory business. Dr. Metters graduated with a BS in biochemistry from the University of Manchester Institute for Science and Technology and obtained her PhD from the Imperial College of Science and Technology. She is an author on more than 70 publications and has been listed on 29 patents. She also serves on the board of directors of Pharmaxis and scientific advisory boards of Bridge Medicines and Tri-Institutional Therapeutics Discovery Institute.